Stock 688578 SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shanghai Allist Pharmaceuticals Co., Ltd.

Equities

688578

CNE100005XJ7

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 31/05/2024 am IST 		5-day change 1st Jan Change
58.12 CNY +0.64% Intraday chart for Shanghai Allist Pharmaceuticals Co., Ltd. +2.22% +39.51%
09/05 Abbisko Cayman Unit's Cancer Drug To Be Clinically Tested in Combination with Shanghai Allist's Furmonertinib MT
25/04 Shanghai Allist Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • The company's profit outlook over the next few years is a strong asset.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

  • With a 2024 P/E ratio at 25.21 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The company appears highly valued given the size of its balance sheet.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. Stock Shanghai Allist Pharmaceuticals Co., Ltd.
+39.51% 3.61B -
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
B+
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
B+
ARGENX SE Stock argenx SE
-0.82% 21.96B
B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
C+
INSMED INCORPORATED Stock Insmed Incorporated
+77.64% 8.87B
C
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 688578 Stock
  4. Ratings Shanghai Allist Pharmaceuticals Co., Ltd.